KSD-101 in Patients With EBV-associated Hematological Malignancies

Inclusion Criteria: * Patients with EBV-associated hematological malignancies who receive KSD-101 Vaccine Therapy (non-genetically modified) . 1. Patients aged 12 years or older on the date of signing the informed consent form. 2. Patients with a confirmed diagnosis of EBV-associated hematological malignancies who either: have failed standard treatment; or have voluntarily chosen KSD-101 as prophylactic / anti-relapse therapy by the patient and/or their legal guardian. * The participant and/or their legal guardian voluntarily agrees to participate and has signed the informed consent form. Exclusion Criteria: * Female patients who are pregnant (positive urine or serum pregnancy test), breastfeeding, or male/female patients planning to conceive within 1 year after enrollment. * Patients positive for hepatitis B surface antigen (HBsAg) or hepatitis B core antibody (HBcAb) with peripheral blood HBV DNA titer above the upper limit of normal; patients positive for anti-HCV antibody and peripheral blood HCV RNA; patients positive for anti-HIV antibody; or patients positive for syphilis-specific antibody. * Patients with central nervous system (CNS) involvement (e.g., cerebral edema requiring steroid intervention, or progressive brain metastasis). * Patients with uncontrolled infectious disease within 4 weeks prior to screening. * Patients with severe underlying diseases, including cardiovascular disease, respiratory disease, renal insufficiency, coagulation disorders, autoimmune disease, or immunodeficiency disease. * Patients who have received prophylactic live or attenuated live vaccines within 4 weeks prior to screening. * Patients who have participated in other clinical studies within 4 weeks prior to screening. * Patients with a history of severe drug allergy or penicillin allergy. * Patients with a history of drug abuse or addiction. * Any other conditions deemed inappropriate for study enrollment by the investigator team.